There are currently 46 clinical trials in Port Orange, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Progressive Medical Research, Advanced Medical Research Center, Accord Clinical Research, LLC and Novartis Investigative Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
NCT06176196
Recruiting
The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/29/2024
Locations: Brain & Spine Institute Of Port Orange, Port Orange, Florida
Conditions: Painful Lumbosacral Radiculopathy
Register for Updates
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173
Recruiting
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/29/2024
Locations: Progressive Medical Research, Port Orange, Florida
Conditions: Alzheimer Disease
Register for Updates
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
NCT06034743
Recruiting
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at ba... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/27/2024
Locations: Research Site, Port Orange, Florida
Conditions: Uncontrolled Hypertension, Resistant Hypertension
Register for Updates
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
05/24/2024
Locations: Progressive Medical Research, Port Orange, Florida
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Progressive Medical Research, Port Orange, Florida
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin al... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/22/2024
Locations: Research Site, Port Orange, Florida
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial)
NCT05989711
Recruiting
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/14/2024
Locations: Altimmune Clinical Study Site, Port Orange, Florida
Conditions: Non-Alcoholic Steatohepatitis (NASH)
Register for Updates
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935
Recruiting
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
05/09/2024
Locations: Advanced Medical Research Center, Port Orange, Florida
Conditions: Eosinophilic Esophagitis
Register for Updates
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2024
Locations: Advanced Medical Research Center, Port Orange, Florida
Conditions: Ulcerative Colitis
Register for Updates
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT06005597
Recruiting
The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability of obicetrapib 10mg and ezetimibe 10mg fixed dose combination as an adjunct to diet and maximally tolerated lipid-lowering therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Progressive Medical Research, Port Orange, Florida
Conditions: Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Register for Updates
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
NCT06083753
Recruiting
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
04/30/2024
Locations: Accel Research Sites Network - Brain & Spine Institute, Port Orange, Florida
Conditions: Relapsing Remitting Multiple Sclerosis
Register for Updates
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
NCT05637801
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/22/2024
Locations: Progressive Medical Research, Port Orange, Florida
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Register for Updates